We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Proteonomix Senior Management Meets With Investment Community

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteonomix Senior Management Meets With Investment Community"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Proteonomix, Inc., has announced that Michael Cohen, Chief Executive Officer of Proteonomix and Ian McNiece, the Company's Chief Scientific Officer met with the team at Gilford Securities, the Company's Investment Banker, and Aegis Capital.

They updated them on the development of the Company's technology and the Company's technical position in several different areas of research and development.

Proteonomix CEO Michael Cohen stated, "Proteonomix is on the cusp of entering a new phase of its development and well on its way to becoming a significant force in the biotech world. We are at present not covered by any analysts in the industry and hope to gain such coverage in the near future. We anticipate that such coverage will assist the investing public is recognizing the achievements of Proteonomix both in bringing our Proteoderm anti-aging skin care line to the point where marketing can commence, as well as moving ever closer to commencement of clinical trials for our StromaCel cardiovascular disease therapy and our UMK-121 liver treatment."

Ian McNiece, the Proteonomix Chief Scientific Officer and a member of the Board, noted, "Our Company has made extraordinary progress on a limited budget both in the realm of product development and in its working relationship with the academic community. Our anticipated clinical trial moves ever closer to fruition and the Company's patent position is remarkable for such an early stage company."

The Company will be filing a version of the PowerPoint presentation made today, along with the Form 8-K filing for this press release.